
WHAT IS CLAIMED IS:

1. Use of a pharmaceutical composition in the manufacture of a medicament for reducing hyperpigmentation in a subject, wherein an effective amount of a pharmaceutical composition is to be administered to a skin site of a subject in need thereof, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (I) or a pharmaceutically acceptable salt thereof:




(I),

wherein each of R_1, R_2, R_3, R_4, and R_8 independently, is H, halogen, thiol, hydroxyl, C1-4 alkyl, C2-4 alkenyl, OR_5, $COOR_6$, or $-OC(=O)R_7$; and

wherein each of R_5, R_6, and R_7 are independently H, or C1-4 alkyl.

2. The use of claim 1, wherein the compound of Formula (I) has following structure:



(I-A), wherein each of R_1, R_2, R_3, and R_4 is set forth in claim 1.

3. The use of claim 1 or claim 2, wherein at least one of R_1, R_2, R_3, and R_4 is hydroxyl or methoxy.


4. The use of claim 3, wherein at least three of R_1, R_2, R_3, and R_4 are hydroxyl or methoxy.


5. The use of claim 1 or claim 2, wherein at least one of R_1, R_2, R_3, and R_4 is $OC(=O)R_7$, in which R_7 is C1-4 alkyl, optionally methyl.

6. The use of claim 5, wherein at least three of R_1, R_2, R_3, and R_4 are $OC(=O)R_7$, in which R_7 is C1-4 alkyl, optionally methyl.


7. The use of any one of claims 1 and 3-6, wherein R_8 is hydroxyl.


8. The use of claim 1, wherein the compound has one of the following structures:




,


,




,


,



, and



.

9. The use of any one of claims 1-8, wherein the pharmaceutically acceptable carrier comprises a non-ionic surfactant having a hydrophilic-lipophilic balance value (HLB value) greater than 5, a solvent, a buffer agent, an oil phase, or a combination thereof.

10. The use of claim 9, wherein the non-ionic surfactant comprises polyoxyl castor oil, and/or polyoxyl hydrogenated castor oil.

11. The use of claim 9 or claim 10, wherein the pharmaceutically acceptable carrier comprises the solvent, which is a polyol or a polymer thereof, acetone, dimelthyl sulfoxide, glycerol, alcohol, or a combination thereof; optionally wherein the polyol or polymer thereof is ethylene glycol, polyoxyethylene, polyethylene glycol, or propylene glycol.

12. The use of any one of claims 9-11, wherein the pharmaceutically acceptable carrier comprises the oil phase, which comprises soybean oil and/or medium-chain triglycerides.

13. The use of any one of claims 1-12, wherein the pharmaceutical composition comprises a plurality of nanoparticles formed by the pharmaceutically acceptable carrier and the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

14. The use of claim 13, wherein the nanoparticles have an average particle size of up to 200 nm and a polydispersity index (PDI) value of up to 0.4.

15. The use of claim 13 or claim 14, wherein the pharmaceutically acceptable carrier comprises the non-ionic surfactant and wherein the weight ratio between the compound of Formula (I) or the pharmaceutically acceptable salt thereof to the non-ionic surfactant ranges from 1:1 to 1:1000, optionally 1:1 to 1:500.

16. The use of any one of claims 1-15, wherein the pharmaceutical composition is to be administered to the skin site via intradermal injection or topical application.

17. The use of any one of claims 1-16, wherein the pharmaceutical composition

further comprises an active agent for reducing hyperpigmentation, wherein the active agent is different from the compound or the pharmaceutically acceptable salt thereof.

18. The use of any one of claims 1-17, wherein the the subject is to be further administered an active agent for reducing hyperpigmentation, wherein the active agent is different from the compound or the pharmaceutically acceptable salt thereof.

19. The use of any one of claims 1-18, wherein the pharmaceutical composition further comprises an antioxidant.

20. The use of any one of claims 1-18, wherein the pharmaceutical composition is free of water and/or an antioxidant.